PRMT5 and central nervous system cancer: For validation, the effect of the PRMT5 inhibitors LLY-283 and GSK591 on cell viability was confirmed using full growth inhibition curves in five patient-derived H3K27M DMG cell lines, as well as in a sixth paediatric glioma line with a H3G34R mutation (Fig. 2A).